(SDGR) Schrodinger - Overview
Stock: Software, Drug Discovery, Platform, Simulations
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 60.7% |
| Relative Tail Risk | -12.3% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.86 |
| Alpha | -67.78 |
| Character TTM | |
|---|---|
| Beta | 1.322 |
| Beta Downside | 0.905 |
| Drawdowns 3y | |
|---|---|
| Max DD | 76.63% |
| CAGR/Max DD | -0.22 |
Description: SDGR Schrodinger January 15, 2026
Schrödinger, Inc. (NASDAQ: SDGR) provides a physics-based computational platform that accelerates molecular design for pharmaceuticals and advanced materials, operating through two distinct segments: a Software business that licenses the platform to life-science and materials-science firms, and a Drug Discovery business that builds its own pre-clinical and clinical pipeline while partnering with pharma companies such as Novartis.
In FY 2023 the company reported total revenue of approximately $120 million, with the Software segment accounting for roughly 80 % of sales and delivering a 15 % year-over-year growth rate; the Drug Discovery segment contributed the remainder and now supports three IND-stage candidates. As of the latest quarter, Schrödinger held about $250 million in cash and marketable securities, giving it an estimated 18-month runway at current burn rates.
Key macro drivers for Schrödinger include the expanding global spend on biotech R&D (projected ~10 % CAGR through 2028) and the accelerating adoption of AI-enhanced computational chemistry, which is reducing drug-discovery timelines and capital requirements. Within the Health-Care Technology sub-industry, firms that can demonstrably shorten the lead-optimization phase are gaining premium valuations.
For a deeper quantitative comparison of SDGR’s valuation metrics, see the ValueRay platform.
Piotroski VR‑10 (Strict, 0-10) 2.0
| Net Income: -176.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.01 > 0.02 and ΔFCF/TA 25.24 > 1.0 |
| NWC/Revenue: 127.1% < 20% (prev 178.6%; Δ -51.47% < -1%) |
| CFO/TA -0.00 > 3% & CFO -1.12m > Net Income -176.0m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 3.25 > 1.5 & < 3 |
| Outstanding Shares: last quarter (73.6m) vs 12m ago 1.10% < -2% |
| Gross Margin: 58.16% > 18% (prev 0.65%; Δ 5751 % > 0.5%) |
| Asset Turnover: 38.84% > 50% (prev 28.89%; Δ 9.96% > 0%) |
| Interest Coverage Ratio: -5.36 > 6 (EBITDA TTM -140.8m / Interest Expense TTM 27.4m) |
Altman Z'' -3.60
| A: 0.50 (Total Current Assets 471.7m - Total Current Liabilities 145.1m) / Total Assets 653.7m |
| B: -1.01 (Retained Earnings -661.3m / Total Assets 653.7m) |
| C: -0.22 (EBIT TTM -147.1m / Avg Total Assets 661.5m) |
| D: -1.99 (Book Value of Equity -660.5m / Total Liabilities 332.3m) |
| Altman-Z'' Score: -3.60 = D |
Beneish M -3.13
| DSRI: 0.96 (Receivables 57.4m/44.8m, Revenue 257.0m/193.3m) |
| GMI: 1.12 (GM 58.16% / 64.91%) |
| AQI: 0.76 (AQ_t 0.09 / AQ_t-1 0.11) |
| SGI: 1.33 (Revenue 257.0m / 193.3m) |
| TATA: -0.27 (NI -176.0m - CFO -1.12m) / TA 653.7m) |
| Beneish M-Score: -3.13 (Cap -4..+1) = AA |
What is the price of SDGR shares?
Over the past week, the price has changed by -3.44%, over one month by -28.21%, over three months by -27.67% and over the past year by -47.89%.
Is SDGR a buy, sell or hold?
- StrongBuy: 6
- Buy: 0
- Hold: 2
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the SDGR price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 25 | 85.3% |
| Analysts Target Price | 25 | 85.3% |
| ValueRay Target Price | 11.1 | -17.9% |
SDGR Fundamental Data Overview February 04, 2026
P/B = 3.2001
Revenue TTM = 257.0m USD
EBIT TTM = -147.1m USD
EBITDA TTM = -140.8m USD
Long Term Debt = 111.4m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 16.7m USD (from shortTermDebt, last quarter)
Debt = 111.4m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -70.4m USD (from netDebt column, last quarter)
Enterprise Value = 748.4m USD (1.04b + Debt 111.4m - CCE 401.0m)
Interest Coverage Ratio = -5.36 (Ebit TTM -147.1m / Interest Expense TTM 27.4m)
EV/FCF = -220.4x (Enterprise Value 748.4m / FCF TTM -3.40m)
FCF Yield = -0.45% (FCF TTM -3.40m / Enterprise Value 748.4m)
FCF Margin = -1.32% (FCF TTM -3.40m / Revenue TTM 257.0m)
Net Margin = -68.49% (Net Income TTM -176.0m / Revenue TTM 257.0m)
Gross Margin = 58.16% ((Revenue TTM 257.0m - Cost of Revenue TTM 107.5m) / Revenue TTM)
Gross Margin QoQ = 51.61% (prev 47.77%)
Tobins Q-Ratio = 1.14 (Enterprise Value 748.4m / Total Assets 653.7m)
Interest Expense / Debt = 166.9% (Interest Expense 186.0m / Debt 111.4m)
Taxrate = 21.0% (US default 21%)
NOPAT = -116.2m (EBIT -147.1m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 3.25 (Total Current Assets 471.7m / Total Current Liabilities 145.1m)
Debt / Equity = 0.35 (Debt 111.4m / totalStockholderEquity, last quarter 321.4m)
Debt / EBITDA = 0.50 (negative EBITDA) (Net Debt -70.4m / EBITDA -140.8m)
Debt / FCF = 20.75 (negative FCF - burning cash) (Net Debt -70.4m / FCF TTM -3.40m)
Total Stockholder Equity = 364.8m (last 4 quarters mean from totalStockholderEquity)
RoA = -26.61% (Net Income -176.0m / Total Assets 653.7m)
RoE = -48.24% (Net Income TTM -176.0m / Total Stockholder Equity 364.8m)
RoCE = -30.89% (EBIT -147.1m / Capital Employed (Equity 364.8m + L.T.Debt 111.4m))
RoIC = -31.86% (negative operating profit) (NOPAT -116.2m / Invested Capital 364.8m)
WACC = 9.74% (E(1.04b)/V(1.15b) * Re(10.79%) + (debt cost/tax rate unavailable))
Discount Rate = 10.79% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 1.01%
Fair Price DCF = unknown (Cash Flow -3.40m)
EPS Correlation: -9.33 | EPS CAGR: 21.96% | SUE: 1.92 | # QB: 3
Revenue Correlation: 31.06 | Revenue CAGR: 4.43% | SUE: 0.91 | # QB: 1
EPS next Quarter (2026-03-31): EPS=-0.51 | Chg30d=-0.023 | Revisions Net=+3 | Analysts=5
EPS next Year (2026-12-31): EPS=-1.23 | Chg30d=-0.130 | Revisions Net=+0 | Growth EPS=+37.7% | Growth Revenue=+19.8%